PLUR NASDAQ
Credit Risk of going bust: higher than 91% of companies Debt: 74.3% of company value Bonds: none of note held by US funds details ▾
Total debt $34.9M against a stock market value of $12.1M.
Distance to default 1.39 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $27.4M (short-term plus half of long-term), stock volatility 73.8%; Altman Z'' -74.81. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Haifa, HA 3508409
IL
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Manieu Alexandre Wei | P-Purchase | 833,334 | — | 2026-10-23 |
| Manieu Alexandre Wei | P-Purchase | 833,334 | — | 2026-10-23 |
| Manieu Alexandre Wei | M-Exempt | 641 | — | 2026-08-25 |
| SHORRER DORON | A-Award | 31,569 | — | 2026-08-20 |
| Manieu Alexandre Wei | A-Award | 180,000 | — | 2026-08-20 |